DEA Approves THC Medicine for Schedule 2
The Drug Enforcement Administration (DEA) has given approval to a pharmaceutical THC product.
Syndros.
After waiting roughly two years, the pharmaceutical drug company Insys has received approval from the DEA for their product Syndros. Syndros, according to Westword, is “an oral remedy containing THC”, which has been approved to treat nausea and vomiting, particular for cancer patients going through chemotherapy.
The DEA’s approval of Syndros flies contrary to their stance of cannabis being a schedule 1 drug, meaning it has no known medical value. That can’t, however, be true if one of its primary compounds has been proven to being medically beneficial, and has been approved for medical use.
Insys, the makers of Syndros, donated half a million dollars to the primary campaign working to defeat a marijuana legalization initiative on last year’s ballot in Arizona.
